Li 2017c.

Methods	Study design: Randomised clinical trial Study duration: January 2010 to January 2015 Duration of follow‐up: 1 year Setting: Hospital
Participants	Age (mean ± SD): 61.3 ± 2.5 years Male (n/total): 100/186 Tumour diameter (mean ± SD, range): 5.2 ± 1.4 cm, 4.5‐8.7 cm
Interventions	TACE + RFA group (n = 93) TACE: Chemotherapeutic drugs: cisplatin 50 mg, epirubicin 40 mg, and hydroxy camptothecin 30 mg RFA: The interval between TACE and RFA was 1 week. TACE group (n = 93): TACE: Chemotherapeutic drugs: cisplatin 50 mg, epirubicin 40 mg, and hydroxy camptothecin 30 mg
Outcomes	Tumour response: Classified as obvious effect, moderate effect, and no effect; measured at 12 months after treatment Adverse events Quality of life: assessed by QOL questionnaire; assessed at 1 year after treatment
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.